The COVID-19 pandemic has threatened people's lives and damaged their health. We understand the intense pressure to increase testing capacity to manage the ongoing outbreak. Therefore, BioVendor Group has developed automated immunoassays to detect SARS-CoV-2 antigen and anti-SARS-CoV-2 antibodies.
The fully automated CLIA antigen assay is intended for high-throughput testing of the population for COVID-19 disease. The antibody detection CLIA tests will help to determine the immune reaction to SARS-CoV-2.